Sarepta Therapeutics: Why Is SRPT Stock Crashing?
1. Sarepta's stock fell over 35% after FDA concerns over Elevidys. 2. FDA may force Elevidys withdrawal following ties to third patient death. 3. Elevidys accounts for 43% of Sarepta's revenue, posing existential risks. 4. Company's defiance creates uncertainty, impacting investor confidence significantly. 5. Regulatory concerns highlight risks of single-stock investments in biotech.